Market Trends of Global Antisense and RNAi Therapeutics Industry
This section covers the major market trends shaping the Antisense & RNAi Therapeutics Market according to our research experts:
RNA Antisense is Expected to Witness High Growth Over the Forecast Period
RNA antisense therapeutics are widely used in the treatment of rare genetic disorders such as spinal muscular atrophy, Duchenne muscular dystrophy (DMD), and hereditary transthyretin amyloidosis (hATTR). Furthermore, the factors that contribute to the growth of this market include a surge in awareness related to the treatment of these rare genetic diseases. Thus, the surge in awareness leads to a rise in demand for RNA antisense therapeutics.
Similarly, factors such as the high cost of RNA antisense therapies such as Spinraza offered by Biogen Inc. and Exondys 51 offered by Sarepta Therapeutics, Inc. and lead to a surge in revenues in the market. For instance, according to a report published by Institute for Clinical and Economic Review (ICER) in 2109, Spinraza's price for patients with presymptomatic spinal muscular atrophy is between $72,000-$130,000 for the first year of treatment. Furthermore, recent product approvals in the market lead to a surge in demand for novel and advanced RNA antisense therapeutics thereby driving the growth of the market. For instance, in February 2021, Sarepta Therapeutics, Inc. received US Food and Drug Administration (US FDA) approval for AMONDYS 45 (casimersen), an antisense oligonucleotide. Furthermore, AMONDYS 45 is indicated for the treatment of DMD. Hence, the factors mentioned above contribute to the growth of the RNA antisense market.
North America is Expected to Dominate the Antisense and RNAi Therapeutics Market
North America is expected to dominate the market. This is due to the high usage of antisense and RNAi therapeutics such as Spinraza offered by Biogen Inc., Onpattro and Givlaari offered by Alnylam Pharmaceuticals, Inc., and others in the region. In addition, other factors that contribute to the growth of the market in the region include the availability of advanced antisense and RNAi therapeutics. Furthermore, the presence of well-established healthcare infrastructure in the region leads to a surge in early screening of rare diseases which in turn leads to a surge in demand for antisense and RNAi therapeutics. For instance, Cure SMA is a non-profit organization dedicated to promoting and supporting research related to spinal muscular atrophy. Furthermore, in June 2021, Cure SMA reported that 85% of newborns in the United States were screened for spinal muscular atrophy.
In addition, in August 2022, Cure SMA announced the addition of 9 new spinal muscular atrophy screening centers to its Care Center Network. In addition, currently, there are 27 such care centers in this network across the United States. Thus, this leads to a surge in early screening in the region which in turn leads to a surge in demand for antisense and RNAi therapeutics.
Therefore, owing to the previously mentioned factors the growth of the market studied is anticipated in the North America Region.
